Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
复制标题
DOI：
10.1016/s0140-6736(08)61764-x
复制
发表时间：
2009-01-03
期刊：
影响因子：
168.9
通讯作者：
Davis, John M.
中科院分区：
文献类型：
--
作者：
Leucht, Stefan;Corves, Caroline;Davis, John M.
背景由于第二代抗精神病药物是否优于第一代抗精神病药物的争论，我们对随机对照试验进行了荟萃分析，以比较这两类药物对精神分裂症患者的疗效。方法我们比较了9种第二代抗精神病药物与第一代药物的总体疗效（主要结果），阳性，阴性和抑郁症状，复发，生活质量，锥体外系副作用，体重增加，和sediting.Findings我们包括150双盲，大多是短期的，研究，与21533参与者。我们排除了开放性研究，因为它们系统地支持第二代药物。其中4种药物的总体疗效优于第一代抗精神病药物，具有小至中等效应量（氨磺必利-0.31 [95%CI-0.44至-0.19，p
Background Because of the debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs, we did a meta-analysis of randomised controlled trials to compare the effects of these two types of drugs in patients with schizophrenia.Methods We compared nine second-generation antipsychotic drugs with first-generation drugs for overall efficacy (main outcome), positive, negative and depressive symptoms, relapse, quality of life, extrapyramidal side-effects, weight gain, and sedation.Findings We included 150 double-blind, mostly short-term, studies, with 21533 participants. We excluded open studies because they systematically favoured second-generation drugs. Four of these drugs were better than first-generation antipsychotic drugs for overall efficacy, with small to medium effect sizes (amisulpride -0.31 [95% Cl -0.44 to -0.19, p